Upregulated endothelin system in diabetic vascular dysfunction and early retinopathy is reversed by CPU0213 and total triterpene acids from Fructus Corni.
1. The aims of the present study were to examine whether: (i) upregulation of the endothelin (ET) pathway is involved in impairment of vascular relaxation and early retinopathy in diabetic rats; and (ii) vascular and retinal abnormalities respond to the total triterpene acid (TTA) isolated from Fructus Corni compared with responses to the novel endothelin receptor antagonist CPU0213 and aminoguanidine (AMG), a special antagonist for advanced glycation end-products (AGE) and inducible nitric oxide synthase (iNOS). 2. Male Sprague-Dawley rats were randomized into five groups, namely a normal control and four diabetic groups, which included an untreated diabetic group and groups treated with AMG (100 mg/kg, i.g.), CPU0213 (30 mg/kg, s.c.) or TTA (50 mg/kg, i.g.). Diabetes was induced by single injection of streptozotocin (60 mg/kg, i.p.) on the 1st day. The mRNA expression of prepro-endothelin-1 (ppET-1), endothelin-converting enzyme (ECE) and iNOS in the thoracic aorta and mRNA for ET(A) receptors and iNOS in the retina were detected by reverse transcription-polymerase chain reaction. Vasorelaxation to acetylcholine (ACh) and functional assessment of nitric oxide (NO) bioavailability was determined in the thoracic aorta. 3. We observed upregulated mRNA expression of iNOS, ppET-1 and ECE in the thoracic aorta and upregulated mRNA for the ET(A) receptor and iNOS in the retina in the untreated diabetic group. Vasodilatation mediated by ACh and NO bioavailability were markedly reduced in the thoracic aorta compared with the normal control group. These abnormalities were essentially reversed by TTA, CPU0213 or AMG, with the exception with that AMG did not modify vasodilatation to ACh. 4. These data suggest that upregulation of gene transcription of the ET system mediates depressed vasorelaxation, NO bioavailability and changes in iNOS and ET(A) receptors that reflect early retinopathy in diabetic rats. Total triterpene acid, in terms of pharmacological properties resembling the endothelin receptor antagonist CPU0213, is effective in normalizing expression of the ET system and iNOS in early diabetic retinopathy and vasculaopathy.
Su
Wei
W
Research Division of Pharmacology, China Pharmaceutical University, Nanjing, China.
Dai
De-Zai
DZ
Liu
Hao-Ran
HR
Na
Tao
T
Dai
Yin
Y
D000818:Animals; D001013:Aorta, Thoracic / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D016282:Aspartic Acid Endopeptidases / Q000235:genetics; D029768:Cornus / Q000737:chemistry*; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D065130:Endothelin A Receptor Antagonists; D019332:Endothelin-1 / Q000235:genetics; D000072396:Endothelin-Converting Enzymes; D006146:Guanidines / Q000627:therapeutic use; D008297:Male; D008666:Metalloendopeptidases / Q000235:genetics; D052247:Nitric Oxide Synthase Type II / Q000037:antagonists & inhibitors / Q000235:genetics; D011720:Pyrazoles / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D044022:Receptor, Endothelin A / Q000235:genetics; D012160:Retina / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D013895:Thoracic Arteries / Q000187:drug effects / Q000503:physiopathology; D014315:Triterpenes / Q000627:therapeutic use*; D015854:Up-Regulation; D014664:Vasodilation / Q000187:drug effects / Q000502:physiology
C513821:CPU0213; D065130:Endothelin A Receptor Antagonists; D019332:Endothelin-1; D006146:Guanidines; D011720:Pyrazoles; D012333:RNA, Messenger; D044022:Receptor, Endothelin A; D014315:Triterpenes; D052247:Nitric Oxide Synthase Type II; C496318:Nos2 protein, rat; D016282:Aspartic Acid Endopeptidases; D008666:Metalloendopeptidases; D000072396:Endothelin-Converting Enzymes; C004479:pimagedine